Literature DB >> 7486186

Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs.

T Kamibayashi1, Y Hayashi, T Mammoto, A Yamatodani, K Sumikawa, I Yoshiya.   

Abstract

BACKGROUND: Dexmedetomidine, an alpha 2-adrenergic agonist, can prevent the genesis of halothane/epinephrine dysrhythmias through the central nervous system. Because stimulation of alpha 2 adrenoceptors in the central nervous system enhances vagal neural activity and vagal stimulation is known to inhibit digitalis-induced dysrhythmias, dexmedetomidine may exert the antidysrhythmic property through vagal stimulation. To address this hypothesis, the effect of dexmedetomidine in vagotomized dogs was examined and compared with that in intact dogs. In addition, the effect of vagotomy on the antidysrhythmic action of doxazosin, an alpha 1 antagonist, was studied.
METHODS: Adult mongrel dogs were anesthetized with halothane (1.3%) and monitored continuously for systemic arterial pressure and premature ventricular contractions. Animals were divided into two groups receiving bilateral vagotomy or sham operation. The dysrhythmia threshold was expressed by the dysrhythmogenic dose of epinephrine, defined as the smallest dose producing four or more premature ventricular contractions within a 15-s period, and plasma concentration of epinephrine at the time when the dysrhythmogenic dose was reached. The threshold was determined in the presence of dexmedetomidine (a selective alpha 2 agonist that crosses the blood-brain barrier) and doxazosin (a selective alpha 1 antagonist that does not penetrate the blood-brain barrier) in the two groups. In addition, the effect of dexmedetomidine in the presence of atropine methylnitrate instead of vagotomy was examined.
RESULTS: Vagotomy did not affect the basal vulnerability to halothane/epinephrine dysrhythmias significantly. Although dexmedetomidine dose-dependently prevented the genesis of the dysrhythmias in intact dogs, the beneficial effect of dexmedetomidine was abolished in both the vagotomized and the atropine-treated dogs. On the other hand, vagotomy did not change the antidysrhythmic property of doxazosin.
CONCLUSIONS: The vagus nerve plays an important role in the prevention of halothane/epinephrine dysrhythmias by dexmedetomidine in dogs. However, resting vagal tone neither modulates the onset of halothane/epinephrine dysrhythmias nor affects the antidysrhythmic action of doxazosin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486186     DOI: 10.1097/00000542-199511000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  21 in total

1.  Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease.

Authors:  Nelson H Burbano; Andrea V Otero; Donald E Berry; Richard A Orr; Ricardo A Munoz
Journal:  Intensive Care Med       Date:  2011-12-13       Impact factor: 17.440

2.  Effects of dexmedetomidine on cerebral circulation and systemic hemodynamics after cardiopulmonary resuscitation in dogs.

Authors:  Hiroki Iida; Mami Iida; Hiroto Ohata; Tomohiro Michino; Shuji Dohi
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

3.  The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways.

Authors:  M Iwasaki; Y Hayashi; T Kamibayashi; A Yamatodani; T Mashimo
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 4.  Dexmedetomidine: antiarrhythmic effects in the pediatric cardiac patient.

Authors:  Joseph D Tobias; Constantinos Chrysostomou
Journal:  Pediatr Cardiol       Date:  2013-02-24       Impact factor: 1.655

5.  A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration.

Authors:  Tivadar Orban; Henri Leinonen; Tamar Getter; Zhiqian Dong; Wenyu Sun; Songqi Gao; Alexander Veenstra; Hossein Heidari-Torkabadi; Timothy S Kern; Philip D Kiser; Krzysztof Palczewski
Journal:  J Pharmacol Exp Ther       Date:  2017-11-21       Impact factor: 4.030

6.  Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations.

Authors:  Constantinos Chrysostomou; Joan Sanchez-de-Toledo; Peter Wearden; Edmund H Jooste; Steven E Lichtenstein; Patrick M Callahan; Tunga Suresh; Elizabeth O'Malley; Dana Shiderly; Jamie Haney; Masahiro Yoshida; Richard Orr; Ricardo Munoz; Victor O Morell
Journal:  Ann Thorac Surg       Date:  2011-09       Impact factor: 4.330

Review 7.  Arrhythmias and vagus nerve stimulation.

Authors:  Youhua Zhang; Todor N Mazgalev
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

8.  The effects of atropine and methotrimeprazine on the epinephrine-induced arrhythmias in halothane-anesthetized dogs.

Authors:  F J Neto; F Massone; S P Luna; A A Camacho; J R Júnior; H M Ishiy
Journal:  Can J Vet Res       Date:  2001-04       Impact factor: 1.310

9.  Survey of utilization of medetomidine and atipamezole in private veterinary practice in Quebec in 2002.

Authors:  M Johanna Kaartinen; Sophie Cuvelliez; Line Brouillard; Yves Rondenay; Jean Jacques Kona-Boun; Eric Troncy
Journal:  Can Vet J       Date:  2007-07       Impact factor: 1.008

10.  The use of dexmedetomidine continuous rate infusion for horses undergoing transvenous electrical cardioversion--A case series.

Authors:  Charlotte Marly-Voquer; Colin C Schwarzwald; Regula Bettschart-Wolfensberger
Journal:  Can Vet J       Date:  2016-01       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.